News

Astonea Labs Limited will hold a board meeting on Saturday, 14th November, 2026, to consider and approve the Unaudited Standalone and Consolidated Financial Results for the half-year ended 30th September, 2026, according to a regulatory filing with the BSE Limited. The company closed its trading window for equity shares from 1st October, 2026, and it will remain closed until 48 hours after the financial results are declared on 14th November, 2026.

Astonea Labs Limited submitted a certificate to the BSE Limited confirming adherence to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, as certified by KFIN Technologies Limited, the company’s Registrar and Share Transfer Agent (RTA).

Astonea Labs Limited informed the BSE Limited that the trading window for its securities, Scrip Code 544409 and ISIN INE0TG901011, will be closed from October 1, 2026, until 48 hours after the declaration of the company’s unaudited financial results for the half-year ending September 30, 2026, in accordance with SEBI regulations. The company has also updated details on the NSDL portal to restrict trading by designated persons and their immediate relatives through freezing of their Permanent Account Numbers at the security level, ISIN INE0TG901011.

Astonea Labs Ltd. approved the immediate termination of agreements with Astonea One Private Limited, superseding a previous deferral from July 24, 2026, and also approved an initial capital investment of up to USD 10,000 in its wholly-owned subsidiary, Astonea LLC, in Wyoming, USA. The company’s board also approved the incorporation of “LONGEVITY SCIENCE PRIVATE LIMITED” as a subsidiary, noting a correction is underway regarding the initially submitted name, and took on record the cost audit report for the financial year ended March 31, 2026.

Astonea Labs announced that the 9th Annual General Meeting(AGM) of the company will be held on 21 August 2026.